Global pharmaceutical company Eli Lilly (NYSE:LLY) reported in Q1 CY2025, with sales up 45.2% year on year to $12.73 billion.

People prescribed GLP-1 agents liraglutide (Saxenda) or semaglutide for weight loss decreased their alcohol intake by almost ...

CVS Caremark decided to stop offering one product in favor of another for weight loss, the latest example of ...

Overall, Wall Street has a Strong Buy consensus rating on Eli Lilly stock based on 18 Buys and one Sell recommendation. The average LLY stock price target of $981 implies about 26.6% upside potential.

A decision is expected in the fourth quarter of 2025.

CVS Health said it will significantly expand access to the blockbuster weight loss drug Wegovy for patients covered by its pharmacy benefit manager, Caremark. Under a new partnership between Caremark ...

Pfizer has not identified one drug to fill gaps, but is betting on specific disease areas, including cancer and obesity, to reverse sales trends. It has invested in oncology drugs, including by ...

Investors will be watching closely whether external partnerships or acquisitions can fill the obesity-drug void and sustain revenue growth as pandemic tailwinds wane. With Q2 results due late July and ...

You can reach Elaine on Signal at elaineywchen.70. Novo Nordisk is expanding its efforts to sell its obesity drug Wegovy directly to patients, striking agreements with telehealth companies ...

Novo Nordisk's diabetes drug Ozempic, which contains the same active ingredient as Wegovy, is already available in Thailand. About 42% of Thailand's adult population is considered obese, and the rate ...

BANGKOK, April 28 (Reuters) - Novo Nordisk (NOVOb.CO), opens new tab has launched its hugely popular weight-loss drug Wegovy in Thailand ... and the rate of obesity in school children surged ...

Roula Khalaf, Editor of the FT, selects her favourite stories in this weekly newsletter. The head of Zealand Pharma has called its $5.3bn partnership with Roche to commercialise an obesity drug ...